mRNA drug to lower blood lipids
According to a placebo-controlled, double-blind study led by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, an experimental treatment may further lower blood triglycerides. The findings were presented at the American College of Cardiology 2024 Scientific Session & Expo and simultaneously published in the New England Journal of Medicine. In the study, 154 adults receiving lipid-lowering therapy with moderate-to-severe hypertriglyceridemia were randomized to receive either 50 mg of Olezarsen, 80 mg of Olezarsen, or placebo. Olezarsen is an antisense oligonucleotide that inhibits APOC3, a gene linked to higher triglyceride levels by targeting its mRNA. The subcutaneous drug was administered every four weeks for one year. Compared to placebo, Olezarsen lowered triglyceride levels by 49% at the 50-mg dose and by...


